<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oxcarbazepine for neuropathic pain - Zhou, M - 2017 | Cochrane Library</title> <meta content="Oxcarbazepine for neuropathic pain - Zhou, M - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007963.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oxcarbazepine for neuropathic pain - Zhou, M - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007963.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007963.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Oxcarbazepine for neuropathic pain" name="citation_title"/> <meta content="Muke Zhou" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Ning Chen" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Li He" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="heli2003new@126.com" name="citation_author_email"/> <meta content="Mi Yang" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cairong Zhu" name="citation_author"/> <meta content="School of Public Health, Sichuan University" name="citation_author_institution"/> <meta content="Fengbo Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD007963.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/12/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007963.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007963.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007963.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Non‐Narcotic [adverse effects, *therapeutic use]; Carbamazepine [adverse effects, *analogs &amp; derivatives, therapeutic use]; Diabetic Neuropathies [*drug therapy]; Neuralgia [*drug therapy]; Numbers Needed To Treat; Oxcarbazepine; Radiculopathy [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007963.pub3&amp;doi=10.1002/14651858.CD007963.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007963\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007963\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","pt","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007963.pub3",title:"Oxcarbazepine for neuropathic pain",firstPublishedDate:"Dec 2, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007963.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007963.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007963.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007963.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007963.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007963.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007963.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007963.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007963.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007963.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5687 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007963.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-sec-0102"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/appendices#CD007963-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/table_n/CD007963StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/table_n/CD007963StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oxcarbazepine for neuropathic pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#CD007963-cr-0002">Muke Zhou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#CD007963-cr-0003">Ning Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#CD007963-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Li He</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#CD007963-cr-0005">Mi Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#CD007963-cr-0006">Cairong Zhu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information#CD007963-cr-0007">Fengbo Wu</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information/en#CD007963-sec-0121">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 December 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007963.pub3">https://doi.org/10.1002/14651858.CD007963.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007963-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007963-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007963-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007963-abs-0001" lang="en"> <section id="CD007963-sec-0001"> <h3 class="title" id="CD007963-sec-0001">Background</h3> <p>Several anticonvulsant drugs are used in the management of neuropathic pain. Oxcarbazepine is an anticonvulsant drug closely related to carbamazepine. Oxcarbazepine has been reported to be efficacious in the treatment of neuropathic pain, but evidence from randomised controlled trials (RCTs) is conflicting. Oxcarbazepine is reportedly better tolerated than carbamazepine. This is the first update of a review published in 2013. </p> </section> <section id="CD007963-sec-0002"> <h3 class="title" id="CD007963-sec-0002">Objectives</h3> <p>To assess the benefits and harms of oxcarbazepine for different types of neuropathic pain. </p> </section> <section id="CD007963-sec-0003"> <h3 class="title" id="CD007963-sec-0003">Search methods</h3> <p>On 21 November 2016, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We searched the Chinese Biomedical Retrieval System (January 1978 to November 2016). We searched the US National Institutes of Health (NIH) databases and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials in January 2017, and we wrote to the companies who make oxcarbazepine and to pain experts requesting additional information. </p> </section> <section id="CD007963-sec-0004"> <h3 class="title" id="CD007963-sec-0004">Selection criteria</h3> <p>All RCTs and randomised cross‐over studies of oxcarbazepine for the treatment of people of any age or sex with any neuropathic pain were eligible. We planned to include trials of oxcarbazepine compared with placebo or any other intervention with a treatment duration of at least six weeks, regardless of administration route and dose. </p> </section> <section id="CD007963-sec-0005"> <h3 class="title" id="CD007963-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD007963-sec-0006"> <h3 class="title" id="CD007963-sec-0006">Main results</h3> <p>Five multicentre, randomised, placebo‐controlled, double‐blind trials with a total of 862 participants were eligible for inclusion in this updated review. Three trials involved participants with painful diabetic peripheral neuropathy (DPN) (n = 634), one included people with neuropathic pain due to radiculopathy (n = 145), and one, which was newly identified at this update, involved participants with peripheral neuropathic pain of mixed origin (polyneuropathy, peripheral nerve injury or postherpetic neuralgia) (n = 83). Some studies did not report all outcomes of interest. For painful DPN, compared to the baseline, the proportion of participants who reported at least a 50% or 30% reduction of pain scores after 16 weeks of treatment in the oxcarbazepine group versus the placebo group were: at least 50% reduction: 34.8% with oxcarbazepine versus 18.2% with placebo (risk ratio (RR) 1.91, 95% confidence interval (CI) 1.08 to 3.39, number of people needed to treat for an additional beneficial outcome (NNTB) 6, 95% CI 3 to 41); and at least 30% reduction: 44.9% with oxcarbazepine versus 28.6% with placebo (RR 1.57, 95% CI 1.01 to 2.44; NNTB 6, 95% CI 3 to 114; n = 146). Both results were based on data from a single trial, since two trials that found little or no benefit did not provide data that could be included in a meta‐analysis. Although these trials were well designed, incomplete outcome data and possible unblinding of participants due to obvious adverse effects placed the results at a high risk of bias. There was also serious imprecision and a high risk of publication bias. The radiculopathy trial reported no benefit for the outcome 'at least 50% pain relief' from oxcarbazepine. In mixed neuropathies, 19.3% of people receiving oxcarbazepine versus 4.8% receiving placebo had at least 50% pain relief. These small trials had low event rates and provided, at best, low‐quality evidence for any outcome. The proportion of people with 'improved' or 'very much improved' pain was 45.9% with oxcarbazepine versus 30.1% with placebo in DPN (RR 1.46, 95% CI 1.13 to 1.88; n = 493; 2 trials; very‐low‐quality evidence) and 23.9% with oxcarbazepine versus 14.9% with placebo in radiculopathy (RR 1.61, 95% CI 0.81 to 3.20; n = 145). </p> <p>We found no trials in other types of neuropathic pain such as trigeminal neuralgia.</p> <p>Trial reports stated that most adverse effects were mild to moderate in severity. Based on moderate‐quality evidence from the three DPN trials, serious adverse effects occurred in 8.3% with oxcarbazepine and 2.5% with placebo (RR 3.65, 95% CI 1.45 to 9.20; n = 634; moderate‐quality evidence). The number needed to treat for an additional harmful (serious adverse effect) outcome (NNTH) was 17 (95% CI 11 to 42). The RR for serious adverse effects in the radiculopathy trial was 3.13 (95% CI 0.65 to 14.98, n = 145). The fifth trial did not provide data. </p> <p>More people withdrew because of adverse effects with oxcarbazepine than with placebo (DPN: 25.6% with oxcarbazepine versus 6.8% with placebo; RR 3.83, 95% CI 2.29 to 6.40; radiculopathy: 42.3% with oxcarbazepine versus 14.9% with placebo; RR 2.84, 95% CI 1.55 to 5.23; mixed neuropathic pain: 13.5% with oxcarbazepine versus 1.2% with placebo; RR 11.51, 95% CI 1.54 to 86.15). </p> </section> <section id="CD007963-sec-0007"> <h3 class="title" id="CD007963-sec-0007">Authors' conclusions</h3> <p>This review found little evidence to support the effectiveness of oxcarbazepine in painful diabetic neuropathy, neuropathic pain from radiculopathy and a mixture of neuropathies. Some very‐low‐quality evidence suggests efficacy but small trials, low event rates, heterogeneity in some measures and a high risk of publication bias means that we have very low confidence in the measures of effect. Adverse effects, serious adverse effects and adverse effects leading to discontinuation are probably more common with oxcarbazepine than placebo; however, the numbers of participants and event rates are low. More well‐designed, multicentre RCTs investigating oxcarbazepine for various types of neuropathic pain are needed, and selective publication of studies or data should be avoided. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007963-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007963-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007963-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007963-abs-0008">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD007963-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007963-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007963-abs-0004" lang="en"> <h3>Oxcarbazepine for neuropathic pain</h3> <p><b>Review question</b> </p> <p>What are the benefits and harms of oxcarbazepine in the treatment of pain caused by nerve damage? </p> <p><b>Background</b> </p> <p>Neuropathic pain is pain that arises from damage to the part of the nervous system that carries sensory information (e.g. pain) to the brain. It is difficult to treat because it tends to be severe, long‐lasting and does not respond well to simple painkillers. Some studies have suggested that a medicine called oxcarbazepine, when given on its own, can relieve pain from nerve damage. </p> <p><b>Study characteristics</b> </p> <p>We searched medical databases for clinical trials looking at the potential benefits and harms of oxcarbazepine in different types of neuropathic pain and found five trials. They involved 634 participants with painful diabetic neuropathy (nerve damage), 145 people with neuropathic pain due to radiculopathy (pain that arises at the point where nerves leave the spinal column), and 83 people with peripheral neuropathic pain of various causes (e.g. peripheral nerve injury (injury to nerves that connect the brain and spinal cord to the rest of the body), polyneuropathy (damage or disease affecting several peripheral nerves) and postherpetic neuralgia (pain that occurs after shingles)). The trials all compared oxcarbazepine with placebo (a pretend treatment). Four trials were funded by the manufacturer of oxcarbazepine. </p> <p><b>Key results and quality of the evidence</b> </p> <p>This review found little evidence to support the effectiveness of oxcarbazepine in painful diabetic neuropathy, neuropathic pain from radiculopathy and mixed neuropathies of various causes. Oxcarbazepine may have some effect, but we cannot be confident that the results would be the same with further studies. Side effects, including those that were serious or made people stop taking the medicine were probably more common with oxcarbazepine than placebo. We know of trials that have not reported results, for example in a form of facial pain called trigeminal neuralgia, and some of the trials we found did not report data in a form that we could analyse. We need more well‐designed studies of oxcarbazepine for various types of neuropathic pain, with large numbers of participants spread over different centres (e.g. difference hospitals and clinics), and all relevant data need to be published or presented. </p> <p>This is the first update of a review published in 2013. Evidence is up to date to November 2016. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007963-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-sec-0108">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-sec-0146">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007963-sec-0108"></div> <h3 class="title" id="CD007963-sec-0109">Implications for practice</h3> <section id="CD007963-sec-0109"> <p>This review found little evidence to support the effectiveness of oxcarbazepine in painful diabetic neuropathy, neuropathic pain from radiculopathy and a mixture of neuropathies. Some very‐low‐quality evidence suggests efficacy but small trials, low event rates, heterogeneity in some measures and a high risk of publication bias means that we have very low confidence in the measures of effect. Adverse effects, serious adverse effects and adverse effects leading to discontinuation are probably more common with oxcarbazepine than placebo, but the numbers of participants or event rates are low. </p> </section> <h3 class="title" id="CD007963-sec-0110">Implications for research</h3> <section id="CD007963-sec-0110"> <p>More well‐designed, large, multicentre, randomised placebo‐ or active‐controlled trials investigating oxcarbazepine for neuropathic pain are needed. The response in neuropathic pain of other causes, and in participants with different pain phenotypes, should be investigated. A dose‐ranging design should be considered to determine whether a dose‐response relationship is present. The speed and period of titration, the observation and management of intolerance, and the most appropriate target dose might be studied further. Selective publication of studies or data should be avoided. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007963-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007963-sec-0022"></div> <div class="table" id="CD007963-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oxcarbazepine versus placebo for painful diabetic neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with painful diabetic neuropathy<br/> <b>Settings:</b> hospitals and clinics<br/> <b>Intervention:</b> oxcarbazepine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oxcarbazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in participant‐reported pain scores by at least 50% from the baseline</b> <br/> VAS<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> <br/> (197 to 617) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.91</b> <br/> (1.08 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB 6</b> (95% CI 3 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in participant‐reported pain scores by at least 30% from the baseline</b> <br/> VAS<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> <br/> (289 to 698) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.57</b> <br/> (1.01 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB 6</b> (95% CI 3 to 114) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global impression of their change in pain</b> <br/> Participant's global assessment of therapeutic effect, 'much' or 'very much'<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b> <br/> (340 to 566) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/> (1.13 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>493<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB 6</b> (95% CI 4 to 14) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse effects</b> <br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (36 to 230) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.65</b> <br/> (1.45 to 9.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>634<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH 17</b> (95% CI 11 to 42) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval;<b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three times: once for inconsistency with other studies not included in the meta‐analysis, once for serious imprecision (small sample size and wide CI) and once for serious study limitations (number of withdrawals not balanced across groups, especially withdrawals due to adverse effects, which led to a high risk of attrition bias. A high risk of publication bias was present.<br/> <sup>2</sup>Downgraded three times: once for serious study limitations (number of withdrawals not balanced across groups, especially withdrawals due to adverse effects, which led to a high risk of attrition bias), once for inconsistency (a high degree of unexplained heterogeneity between the two included RCTs) and once for publication bias.<br/> <sup>3</sup>Downgraded once for serious imprecision. Event rate was low. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007963-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-sec-0127">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD007963-sec-0023"></div> <section id="CD007963-sec-0024"> <h3 class="title" id="CD007963-sec-0024">Description of the condition</h3> <p>Neuropathic pain is defined as "pain initiated or caused by a primary lesion or dysfunction of the nervous system" (<a href="./references#CD007963-bbs2-0051" title="MerskeyH , BogdukN . Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd Edition. Seattle (WA): IASP Press, 1994. ">Merskey 1994</a>), or more recently as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system" (<a href="./references#CD007963-bbs2-0061" title="TreedeRD , JensenTS , CampbellJN , CruccuG , DostrovskyJO , GriffinJW , et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology2008;70(18):1630‐5. ">Treede 2008</a>). Neuropathic pain is difficult to treat because of its severity, chronicity and resistance to simple analgesics. Neuropathic pain may have its genesis in the brain, spinal cord or peripheral nerves and arises from conditions including radiculopathy (cervical or lumbar), malignancy, infection (e.g. postherpetic neuralgia and HIV‐related neuropathy), injury to the spinal cord, diabetic peripheral neuropathy (DPN), trigeminal neuralgia and complex regional pain syndrome type II (<a href="./references#CD007963-bbs2-0047" title="JensenTS , GottrupH , SindrupSH . The clinical picture of neuropathic pain. European Journal of Pharmacology2001;429(1‐3):1‐11. ">Jensen 2001</a>). The epidemiology of neuropathic pain has not been well described, at least in part because the underlying conditions are so diverse. Current pooled estimates suggest that as much as 3% of the population may be affected by neuropathic pain (<a href="./references#CD007963-bbs2-0033" title="DavisMP , WalshD . Epidemiology of cancer pain and factors influencing poor pain control. American Journal of Hospice and Palliative Care2004;21(2):137‐42. ">Davis 2004</a>; <a href="./references#CD007963-bbs2-0039" title="FoleyKM . Opioids and chronic neuropathic pain. New England Journal of Medicine2003;348(13):1279‐81. ">Foley 2003</a>; <a href="./references#CD007963-bbs2-0042" title="HeliovaaraM , ImpivaaraO , SieversK , MelkasT , KnektP , KorpiJ , et al. Lumbar disc syndrome in Finland. Journal of Epidemiology and Community Health1987;41(3):251‐8. ">Heliovaara 1987</a>; <a href="./references#CD007963-bbs2-0057" title="SchmaderKE . Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain2002;18(6):350‐4. ">Schmader 2002</a>; <a href="./references#CD007963-bbs2-0062" title="VermaS , EstanislaoL , SimpsonD . HIV‐associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs2005;19(4):325‐34. ">Verma 2005</a>; <a href="./references#CD007963-bbs2-0064" title="WerhagenL , BudhCN , HultlingC , MolanderC . Neuropathic pain after traumatic spinal cord injury? Relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord2004;42(12):665‐73. ">Werhagen 2004</a>). </p> <p>The underlying mechanisms of neuropathic pain are complicated and unclear (<a href="./references#CD007963-bbs2-0038" title="FinnerupNB , SindrupSH , JensenTS . Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundamental Clinical Pharmacology2007;21(1):129‐36. ">Finnerup 2007</a>). We know that the peripheral and central nervous systems are capable of both structural and functional plastic changes in response to injury and experience. Peripheral changes include the sensitisation of nociceptors, which results in decreased activation thresholds and increased pain in response to a given stimulus, and abnormal neuronal sprouting that leads to expansion of nociceptive receptive fields and ectopic firing of dorsal root ganglia cells. Changes in expression of abnormal sodium and calcium channels are considered instrumental in the generation of spontaneous discharges from injured neurons (<a href="./references#CD007963-bbs2-0027" title="CallinS , BennettMI . Assessment of neuropathic pain. Continuing Education in Anaesthesia, Critical Care and Pain2008;8(6):210‐3. ">Callin 2008</a>). </p> <p>Central changes following peripheral nerve injury include loss of inhibitory effects in the central nervous system and heightened sensitivity of neurons in the spinal cord, which occurs despite reduced peripheral input. Moreover, N‐methyl‐D‐aspartic acid (NMDA) receptors are upregulated and activated, and play an important role in central sensitisation in neuropathic pain. Other important findings include facilitatory descending pathways and the potential relevance of genetic differences between people (<a href="./references#CD007963-bbs2-0027" title="CallinS , BennettMI . Assessment of neuropathic pain. Continuing Education in Anaesthesia, Critical Care and Pain2008;8(6):210‐3. ">Callin 2008</a>; <a href="./references#CD007963-bbs2-0028" title="CarpenterKJ , DickensonAH . Molecular aspects of pain research. Pharmacogenomics Journal2002;2(2):87‐95. ">Carpenter 2002</a>; <a href="./references#CD007963-bbs2-0060" title="SuzukiR , RyghLJ , DickensonAH . Bad news from the brain: descending 5‐HT pathways that control spinal pain processing trends. Trends in Pharmacological Sciences2004;25(12):613‐7. ">Suzuki 2004</a>). </p> <p>Neuropathic pain has a profound effect on quality of life and expenditure on health care (<a href="./references#CD007963-bbs2-0057" title="SchmaderKE . Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain2002;18(6):350‐4. ">Schmader 2002</a>). It remains a major therapeutic challenge despite considerable research efforts over the past few decades. The shared pathophysiology of neuropathic pain and epilepsy supports the rationale for using certain antiepileptic drugs (AEDs) in the treatment of neuropathic pain (<a href="./references#CD007963-bbs2-0036" title="DickensonAH , MatthewsEA , SuzukiR . Neurobiology of neuropathic pain: mode of action of anticonvulsants. European Journal of Pain2002;6 Suppl A:51‐60. ">Dickenson 2002</a>; <a href="./references#CD007963-bbs2-0048" title="JensenTS . Anticonvulsants in neuropathic pain: rationale and clinical evidence. European Journal of Pain2002;6 Suppl A:61‐8. ">Jensen 2002</a>). Several Cochrane Reviews have assessed the effects of individual AEDs in neuropathic pain, including lamotrigine (<a href="./references#CD007963-bbs2-0066" title="WiffenPJ , DerryS , MooreRA . Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD006044.pub4] ">Wiffen 2013</a>), carbamazepine (<a href="./references#CD007963-bbs2-0067" title="WiffenPJ , DerryS , MooreRA , KalsoEA . Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD005451.pub3] ">Wiffen 2014</a>), gabapentin (<a href="./references#CD007963-bbs2-0053" title="MooreRA , WiffenPJ , DerryS , ToelleT , RiceAS . Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] ">Moore 2014</a>), pregabalin (<a href="./references#CD007963-bbs2-0052" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ . Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] ">Moore 2009</a>), valproic acid (<a href="./references#CD007963-bbs2-0040" title="GillD , DerryS , WiffenPJ , MooreRA . Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009183.pub2] ">Gill 2011</a>), phenytoin (<a href="./references#CD007963-bbs2-0026" title="BirseF , DerryS , MooreRA . Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009485.pub2] ">Birse 2012</a>), and clonazepam (<a href="./references#CD007963-bbs2-0030" title="CorriganR , DerryS , WiffenPJ , MooreRA . Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009486.pub2] ">Corrigan 2012</a>). These replaced an original review of AEDs for neuropathic pain (<a href="./references#CD007963-bbs2-0065" title="WiffenPJ , McQuayHJ , EdwardsJ , MooreRA . WITHDRAWN: Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3] ">Wiffen 2010</a>), first published in 2005 and now withdrawn. </p> </section> <section id="CD007963-sec-0025"> <h3 class="title" id="CD007963-sec-0025">Description of the intervention</h3> <p>Oxcarbazepine (10,11‐dihydro‐10‐oxo‐5H,dibenz[b,f]azepine‐5‐carboxamide) is the keto analogue of carbamazepine, a sodium channel modulator used primarily in the treatment of epilepsy and trigeminal neuralgia. It has previously been reported to be better tolerated and safer than carbamazepine, with a lower risk of allergic reactions and drug‐drug interactions (<a href="./references#CD007963-bbs2-0023" title="BeydounA , SchmidtD , SouzaJ . Oxcarbazepine versus carbamazepine in trigeminal neuralgia: a meta‐analysis of three double‐blind comparative trials. Neurology2002;58 Suppl 3:A131. ">Beydoun 2002a</a>; <a href="./references#CD007963-bbs2-0032" title="DamM , EkbergR , LoyningY , WaltimoO , JakobsenL . A double‐blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research1989;3(1):70‐6. ">Dam 1989</a>). Three double‐blind, placebo‐controlled trials have evaluated oxcarbazepine in painful diabetic neuropathy. Two trials showed significant pain reduction in participants treated with oxcarbazepine compared with placebo (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>), while the third trial showed no difference in efficacy between oxcarbazepine‐treated and placebo‐treated participants (<a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). </p> <p>Data on the potential efficacy of oxcarbazepine for treating the pain associated with trigeminal neuralgia were derived from an active‐control double‐blind trial (<a href="./references#CD007963-bbs2-0049" title="LindstromP . The analgesic effect of carbamazepine in trigeminal neuralgia. Pain1987;30:S85. ">Lindstrom 1987</a>), and meta‐analyses of three double‐blind comparative trials (<a href="./references#CD007963-bbs2-0023" title="BeydounA , SchmidtD , SouzaJ . Oxcarbazepine versus carbamazepine in trigeminal neuralgia: a meta‐analysis of three double‐blind comparative trials. Neurology2002;58 Suppl 3:A131. ">Beydoun 2002a</a>; <a href="./references#CD007963-bbs2-0024" title="BeydounA , SchmidtD , D'SouzaJ , on behalf of the oxcarbazepine study group. Meta‐analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. 21st American Pain Society Annual Meeting; 2002 Mar 14‐17; Baltimore (MD). ">Beydoun 2002b</a>). These showed that oxcarbazepine produced substantial pain relief in most people with trigeminal neuralgia and that there was no significant difference in pain relief between oxcarbazepine and carbamazepine. Additionally, there was a pooled analysis of seven open‐label clinical trials, sharing the same protocol, of oxcarbazepine in different neuropathic pain conditions (<a href="./references#CD007963-bbs2-0050" title="MagentaP , ArghettiS , DiPalmaF , JannS , SterlicchioM , BianconiC , et al. Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurological Sciences2005;26(4):218‐26. ">Magenta 2005</a>). The results of this analysis suggested that oxcarbazepine administered as monotherapy can relieve pain associated with neuropathies. </p> </section> <section id="CD007963-sec-0026"> <h3 class="title" id="CD007963-sec-0026">Why it is important to do this review</h3> <p>To determine the efficacy of oxcarbazepine for neuropathic pain, we gathered evidence from randomised controlled trials (RCTs) and first published a Cochrane systematic review on this topic in 2013. It concluded that oxcarbazepine was effective in reducing pain in people with DPN, but this conclusion was made based on moderate‐quality evidence from only one RCT (<a href="./references#CD007963-bbs2-0070" title="ZhouM , ChenN , HeL , YangM , ZhuC , WuF . Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD007963.pub2] ">Zhou 2013</a>). We updated this review to consider new, potentially eligible studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007963-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-sec-0027">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-sec-0131">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007963-sec-0027"></div> <p>To assess the benefits and harms of oxcarbazepine for different types of neuropathic pain. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007963-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-sec-0132">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007963-sec-0028"></div> <section id="CD007963-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007963-sec-0030"> <h4 class="title">Types of studies</h4> <p>We included RCTs or randomised cross‐over studies of oxcarbazepine for the treatment of neuropathic pain. Trials were eligible whether published or unpublished. There was no language restriction. We interviewed the study authors by telephone or wrote for clarification if the studies were described as RCTs but there was poor reporting of the methodology. We excluded quasi‐randomised trials and trials described as randomised but which we found not to be adequately randomised or blinded on further examination. </p> </section> <section id="CD007963-sec-0031"> <h4 class="title">Types of participants</h4> <p>Participants of any age or either sex with any neuropathic pain were eligible.</p> </section> <section id="CD007963-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Oxcarbazepine versus placebo or any other intervention, regardless of administration route or dose. We allowed cointerventions if they were offered equally to both arms of the trial. The treatment duration needed to be at least six weeks. </p> </section> <section id="CD007963-sec-0033"> <h4 class="title">Types of outcome measures</h4> <p>We planned to measure outcomes as close to eight weeks (minimum six weeks) as possible. When outcomes were reported after different durations of treatment we extracted the data measured as close to the specified time (eight weeks) as possible, but not less than the minimum. </p> <section id="CD007963-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007963-list-0001"> <li> <p>Reduction in participant‐reported pain scores by at least 50% from the baseline, measured on commonly used pain scales such as a visual analogue scale (VAS), verbal rating scale (VRS), numerical rating scale (NRS) (<a href="./references#CD007963-bbs2-0068" title="WilliamsonA , HoggartB . Pain: a review of three commonly used pain rating scales. Journal of Clinical Nursing2005;14(7):798‐804. ">Williamson 2005</a>), and the Faces Pain Scale (FPS) (<a href="./references#CD007963-bbs2-0025" title="BieriD , ReeveRA , ChampionGD , AddicoatL , ZieglerJB . The Faces Pain Scale for the self‐assessment of the severity of pain experienced by children: development, initial validation and preliminary investigation for ratio scale properties. Pain1990;41(2):139‐50. ">Bieri 1990</a>). </p> </li> </ul> </p> </section> <section id="CD007963-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007963-list-0002"> <li> <p>Reduction in participant‐reported pain scores by at least 30% from the baseline, measured on commonly used pain scales. </p> </li> <li> <p>Participants' global impression of their change in pain.</p> </li> <li> <p>Overall quality of life measures, as changes or levels at eight weeks using the Short Form‐36 (SF‐36) Health Survey (<a href="./references#CD007963-bbs2-0063" title="WareJEJr , SherbourneCD . The MOS 36‐item Short‐Form Health Survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. ">Ware 1992</a>), including the physical health summary, mental health summary and pain subscale. </p> </li> <li> <p>Adverse effects (i.e. classified as any adverse effect; adverse effects leading to withdrawal from treatment; and serious adverse effects that were life‐threatening, required hospitalisation or were fatal). </p> </li> </ul> </p> </section> </section> </section> <section id="CD007963-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007963-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Neuromuscular Specialised Register (21 November 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 21 November 2016, in the Cochrane Register of Studies Online)), MEDLINE (OvidSP; January 1966 to November 2016), Embase (OvidSP; January 1980 to November 2016) and the Chinese Biomedical Retrieval System (January 1978 to November 2016). We also searched the US National Institutes of Health (NIH) database <a href="http://www.ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> (15 January 2017) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>) for registered trials (15 January 2017). </p> <p>The detailed search strategies are in the appendices: Cochrane Neuromuscular Specialised Register (<a href="./appendices#CD007963-sec-0114">Appendix 1</a>), CENTRAL (<a href="./appendices#CD007963-sec-0115">Appendix 2</a>), MEDLINE (<a href="./appendices#CD007963-sec-0116">Appendix 3</a>), Embase (<a href="./appendices#CD007963-sec-0117">Appendix 4</a>), and the Chinese Biomedical Retrieval System (<a href="./appendices#CD007963-sec-0118">Appendix 5</a>). In the US NIH database and WHO ICTRP Search Portal, we used the keywords 'oxcarbazepine' OR 'trileptal' OR 'trexapin' to search possible studies for further assessment, but we did not limit by type of participant or trial design. </p> </section> <section id="CD007963-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We wrote to the companies (e.g. Novartis Pharmaceuticals) who made oxcarbazepine and to pain experts asking for information about other completed or ongoing trials. We examined the Novartis clinical trials results database with the assistance of the Cochrane Neuromuscular Managing Editor. We also searched reference lists of review articles and included studies. </p> </section> </section> <section id="CD007963-sec-0039"> <h3 class="title" id="CD007963-sec-0039">Data collection and analysis</h3> <p>Two review authors (NC and MZ) independently selected the studies for inclusion, assessed their risk of bias and extracted relevant data. For the first version of the review, the Cochrane Neuromuscular Managing Editor also assisted in the identification of trial reports by performing an independent review of English language search results. One review author (NC) entered the data into Review Manager 5 (<a href="./references#CD007963-bbs2-0055" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and a second review author (MZ) checked the data entry. The review authors resolved disagreements through discussion. </p> <section id="CD007963-sec-0040"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NC and MZ) independently scrutinised titles and abstracts identified by the searches to determine which studies might fulfil the selection criteria. We obtained full reports of potentially eligible studies (when available) to determine whether they met inclusion criteria for the review. We excluded studies involving participants with chronic headache and migraine. A third review author (LH) helped to arbitrate if the other two review authors could not reach agreement. </p> <p>We collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. </p> </section> <section id="CD007963-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (NC and MZ) independently extracted data from included trials using a specially designed data extraction form, which they piloted on two studies. They extracted the following data. </p> <p> <ul id="CD007963-list-0003"> <li> <p>Participants: number, age range, gender, type of neuropathic disorder, setting.</p> </li> <li> <p>Intervention: dosing regimen, duration, route of administration.</p> </li> <li> <p>Control: placebo, other intervention.</p> </li> <li> <p>Outcomes: analgesic outcome measures and results, withdrawals and adverse effects (minor and serious). </p> </li> <li> <p>Design: methods of randomisation, study design (parallel group, cross‐over), treatment duration and duration of study follow‐up, and whether specifically designed to measure pain. </p> </li> </ul> </p> <p>We also included 'Risk of bias' criteria on the data extraction form recording sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other concerns about bias. One review author (NC) entered data into Review Manager 5 (<a href="./references#CD007963-bbs2-0055" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and a second review author (MZ) checked the data entry. </p> </section> <section id="CD007963-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MZ and NC) independently assessed 'Risk of bias' according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007963-bbs2-0044" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). They resolved any disagreement by discussion. </p> <p>The review authors considered six specific domains (namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other bias). They assessed each included study in relation to the criteria as low, high or unclear risk of bias. </p> </section> <section id="CD007963-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated risk ratios (RR) with 95% confidence intervals (CIs) (<a href="./references#CD007963-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> <p>For continuous data, we planned to calculate the weighted mean difference (WMD) or standardised mean difference (SMD). The included trials reported only dichotomous outcomes. </p> </section> <section id="CD007963-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to analyse cross‐over trials either using only the data from the first treatment period, or using data from both treatment periods provided that the washout period was adequate. If there had been multiple cross‐over trials, we would have analysed the results with the generic inverse variance method in Review Manager 5 (<a href="./references#CD007963-bbs2-0055" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). For the only included cross‐over trial in the updated review (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>), we reported data from both treatment periods as there was an adequate washout period. </p> </section> <section id="CD007963-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data, such as missing standard deviations, by attempting to contact the trial authors via email or telephone. If participant withdrawal led to missing data, we conducted an intention‐to‐treat (ITT) analysis whenever possible. For dichotomous outcomes, we regarded participants with missing outcome data as treatment failures and included these in the analysis. For continuous outcomes, we planned to carry forward the last recorded value for participants with missing outcome data (<a href="./references#CD007963-bbs2-0045" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> </section> <section id="CD007963-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>We performed formal statistical testing of heterogeneity between the trials using Review Manager 5 (RevMan 2014). We assessed heterogeneity amongst trials using the Chi² test. We used a P value of 0.10 to determine statistical significance. A P value less than 0.10 might indicate a problem with the heterogeneity of combined data. We also used I² values to quantify inconsistency across studies, which reflected the percentage of the variability in effect estimates that was due to heterogeneity rather than sampling error. An I² value between 30% and 50% might represent moderate heterogeneity, while a value above 50% suggests substantial heterogeneity (<a href="./references#CD007963-bbs2-0034" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD007963-sec-0047"> <h4 class="title">Data synthesis</h4> <p>We presented the pooled outcomes data from all similar studies using RRs and 95% CIs.</p> <p>We reported results as number needed to treat for an additional beneficial outcome (NNTB) for the specified percentage change in pain scores, and number needed to treat for an additional harmful outcome (NNTH) for mild and serious adverse drug reactions. </p> <p>We planned to perform analyses using a fixed‐effect model and use a random‐effects model to test the sensitivity of the results to the model. Where appropriate, we combined data from included studies using Review Manager 5 (<a href="./references#CD007963-bbs2-0055" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD007963-sec-0048"> <h5 class="title">'Summary of findings' table</h5> <p>We included a 'Summary of findings' table for comparisons that included more than one trial to present the main findings of the review, including information about quality of evidence, magnitude of effects and sum of available data on the main outcomes (<a href="./references#CD007963-bbs2-0058" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>). We included the following outcomes. </p> <p> <ul id="CD007963-list-0004"> <li> <p>Reduction in participant‐reported pain scores byat least 50% from baseline.</p> </li> <li> <p>Reduction in participant‐reported pain scores by at least 30% from baseline.</p> </li> <li> <p>Participants 'much' or 'very much' improved after 16 weeks of treatment.</p> </li> <li> <p>Serious adverse effects.</p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, inconsistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence (studies that contributed data for the prespecified outcomes) (<a href="./references#CD007963-bbs2-0056" title="RyanR , HillS , Cochrane Consumers and Communication Group. How to GRADE the quality of the evidence, Version 1.0, June 2016. cccrg.cochrane.org/author‐resources (accessed prior to 16 November 2017). ">Ryan 2016</a>). We downgraded the evidence from 'high quality' by one level where one of these factors was present to a serious degree and two levels if very serious. Only RCTs (including randomised cross‐over trials) were eligible for the review and reasons for upgrading (large effect, dose response, and plausible confounding factors) were therefore not applicable. We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007963-bbs2-0044" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>; <a href="./references#CD007963-bbs2-0059" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011b</a>). We used GRADEpro software (<a href="./references#CD007963-bbs2-0041" title="GRADE Working Group, McMaster University. GRADEpro. Version 3.2 for Windows. Hamilton (ON): GRADE Working Group, McMaster University, 2008. ">GRADEpro 2008</a>; <a href="./references#CD007963-bbs2-0056" title="RyanR , HillS , Cochrane Consumers and Communication Group. How to GRADE the quality of the evidence, Version 1.0, June 2016. cccrg.cochrane.org/author‐resources (accessed prior to 16 November 2017). ">Ryan 2016</a>). We justified all decisions to downgrade or upgrade the quality of the evidence using footnotes and made comments to aid the reader's understanding of the review where necessary. </p> </section> </section> <section id="CD007963-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed a post hoc subgroup analysis of different doses of oxcarbazepine for painful diabetic neuropathy. If data had been available, we would have undertaken subgroup analysis according to the types of neuropathic pain (peripheral neuropathic pain and central neuropathic pain). </p> </section> <section id="CD007963-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to examine the effects of excluding studies with a moderate or high risk of bias, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007963-bbs2-0043" title="HigginsJPT , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). Since all the included trials had a similar risk of bias, we did not perform a sensitivity analysis. </p> <p>This review has a published protocol (<a href="./references#CD007963-bbs2-0069" title="ZhouM , HeL , YangM , ChenN , GuoJ , LiQ , YangX , YangJ , ZhuC . Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007963] ">Zhou 2009</a>). We described deviations from the protocol in <a href="#CD007963-sec-0122">Differences between protocol and review</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007963-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007963-sec-0051"></div> <section id="CD007963-sec-0052"> <h3 class="title">Description of studies</h3> <section id="CD007963-sec-0053"> <h4 class="title">Results of the search</h4> <p>The electronic searches for this update retrieved 25 references from the Cochrane Neuromuscular Specialised Register, 30 from CENTRAL, 91 from MEDLINE, 123 from Embase, three from Database of Abstracts of Reviews of Effects (DARE), 48 from the Chinese Biomedical Retrieval System, 63 from <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and 70 from the WHO ICTRP. From the searches in other resources, including replies from pharmaceutical companies, company databases and the reference lists of found articles, we retrieved 10 additional references, one of which was an ongoing trial (<a href="./references#CD007963-bbs2-0019" title="NCT02219373 . Gabapentin and oxcarbazepine for chronic neuropathic pain in children and adolescents: a clinical effectiveness study. clinicaltrials.gov/ct2/show/NCT02219373 (accessed 15 January 2017). ">NCT02219373</a>). One study in peripheral neuropathic pain (NCT01302275) categorised as ongoing in the previous version of this review has since been completed and we included it in the review (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). From the total of 404 references (excluding duplicates), we identified 48 records reporting the efficacy or safety, or both, of oxcarbazepine for the treatment of different neuropathic pain conditions. Most records did not meet the entry criteria of the present review because the titles or abstracts indicated that they were open‐label clinical trials comparing the efficacy and safety outcomes at the end of studies with the baseline conditions. Of the 29 remaining references selected for further consideration, we excluded 14 references for 13 studies (see <a href="./references#CD007963-sec-0125" title="">Characteristics of excluded studies</a> table). We included five trials (described in 14 references) that met the eligibility criteria (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>) (see <a href="./references#CD007963-sec-0124" title="">Characteristics of included studies</a> table). </p> <p>In this update, we found one ongoing trial (<a href="./references#CD007963-bbs2-0019" title="NCT02219373 . Gabapentin and oxcarbazepine for chronic neuropathic pain in children and adolescents: a clinical effectiveness study. clinicaltrials.gov/ct2/show/NCT02219373 (accessed 15 January 2017). ">NCT02219373</a>). This is a double‐blind RCT to assess the efficacy and safety of gabapentin and oxcarbazepine for the treatment of chronic neuropathic pain in children. The online report provided explicit inclusion and exclusion criteria and the estimated number of participants to be enrolled was 60. Participants in the two experimental groups receive either gabapentin or oxcarbazepine liquids orally and the dose is gradually increased over 13 days according to the participants' weight, while placebo liquid is escalated in similar mode. The primary outcome measure is the frequency of successful treatment two to eight weeks after assignment of intervention. Secondary outcomes are pain scores at rest and evoked manoeuvres, functional disability scores and frequencies of adverse effects. The trial started in October 2014, and was estimated to be completed in October 2016. The completion date has passed and the study status has not been verified in more than two years up to 15 January 2017, neither have we found a published report. See <a href="./references#CD007963-sec-0126" title="">Characteristics of ongoing studies</a> table. <a href="#CD007963-fig-0001">Figure 1</a> shows a flow chart illustrating study selection. </p> <div class="figure" id="CD007963-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007963-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We obtained all data relating to the included studies from published articles or results reported online. We attempted to contact with authors of the included trials, but received no responses. </p> </section> <section id="CD007963-sec-0054"> <h4 class="title">Included studies</h4> <p>Three included studies involved 634 participants with painful diabetic neuropathy (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>), and one study involved 145 participants with neuropathic pain due to radiculopathy (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). One trial, included for this first time in this updated version, enrolled 83 participants with peripheral neuropathic pain due to polyneuropathy (n = 38), peripheral nerve injury (n = 38) or postherpetic neuralgia (n = 7) (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). We identified no eligible trials of oxcarbazepine for other types of neuropathic pain. </p> <section id="CD007963-sec-0055"> <h5 class="title">Design</h5> <p>Four included trials were from a series of studies supported by the manufacturer of oxcarbazepine (Novartis), so they had similar design, inclusion and exclusion criteria, efficacy and safety assessments (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). They were all placebo‐controlled, double‐blind, parallel‐group trials, conducted in multiple clinics and research centres. The reported study periods differed: a total of 72 weeks for <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, and 18 weeks for <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>, <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>, and <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>. <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a> consisted of a two‐week pre‐randomisation screening phase, an 18‐week double‐blind treatment phase and a 52‐week open‐label extension phase. The double‐blind treatment phase was further divided into a titration period of four weeks and a maintenance period of 12 weeks in each study, and an additional follow‐up period of two weeks for safety monitoring. <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>, <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>, and <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a> consisted of the screening phase (two weeks) and the double‐blind treatment phase (16 weeks). </p> <p><a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> was a placebo‐controlled, double‐blind trial, but it used a cross‐over design. The study period comprised a one‐week drug‐free baseline period and a six‐week treatment period before and after cross‐over. Before each baseline week, there was a washout period of at least one week. </p> </section> <section id="CD007963-sec-0056"> <h5 class="title">Participants</h5> <p>All trials explicitly stated the inclusion and exclusion criteria.</p> <p>The three studies investigating treatment for painful diabetic neuropathy recruited men and non‐pregnant, non‐lactating women aged 18 years or older with an established clinical diagnosis of type 1 or 2 diabetes mellitus and with a history of neuropathic pain for six months to five years prior to study entry (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). Stable diabetic control and a certain pain severity and variability were also required. </p> <p>The radiculopathy trial enrolled participants aged 18 years or older, of both genders, with a diagnosis of radiculopathy and evidence of motor deficit or reflex loss on examination, a history of neuropathic pain for six months or longer, and a VAS score of 50 or higher on a 100‐point scale (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). </p> <p><a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> included men and women aged 18 years or older with definite or probable neuropathic pain for more than three months due to polyneuropathy, peripheral nerve injury or postherpetic neuralgia. The median pain intensity had to be at least 4 on an 11‐point NRS (with 0 being "no pain" and 10 "worst possible pain") during the first drug‐free baseline week. Among the randomised participants, 35 had the 'irritable nociceptor' phenotype, while 62 had the 'non‐irritable' nociceptor phenotype based on quantitative sensory testing (QST). </p> <p>The baseline characteristics of participants were reported to be well matched between groups in each trial in terms of demography, duration of the primary disorders, and duration and severity of neuropathic pain. In total, the studies in this review included 473 males and 389 females, of whom 469 received oral oxcarbazepine, 310 received placebo and 83 received both oxcarbazepine and placebo in order, using a cross‐over design. For the parallel‐group trials, the mean duration of neuropathic pain (2.4 to 7.7 years) and mean VAS score (100‐point scale) of participants before treatment (70.7 to 76.9) in each group were also compared between groups and there were no significant differences. </p> </section> <section id="CD007963-sec-0057"> <h5 class="title">Interventions</h5> <p>After the screening phase, eligible participants were randomised to placebo or to oxcarbazepine treatment with a given target dose. There was only one active group in <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a> (oxcarbazepine 1800 mg/day), <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a> (oxcarbazepine 1200 mg/day), <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a> (oxcarbazepine 1800 mg/day) and <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> (up to oxcarbazepine 2400 mg/day). <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> gave one of three doses of oxcarbazepine (300 mg, 600 mg or 900 mg) twice a day to participants in the different experimental groups. For the present analyses, 83 participants with painful diabetic neuropathy were analysed in the oxcarbazepine 600 mg/day group, 158 in the 1200 mg/day group and 157 in the 1800 mg/day group. A total of 71 participants with pain due to radiculopathy were analysed in the oxcarbazepine 1800 mg/day group, and 83 with painful polyneuropathy, nerve injury pain or postherpetic neuralgia were treated with up to 2400 mg/day dose (up to 1800 mg/day for participants aged 70 years or older). At the beginning of the treatment phase, participants took a small initial dose of study medication (300 mg/day) and then the oxcarbazepine was titrated over three to four weeks according to tolerability or the given maximum dose. During the subsequent maintenance period, treatment remained at the dose reached at the end of the titration period. Participants in the control group received matching placebo tablets. The mean (± standard deviation) oxcarbazepine dose during the maintenance period was 1455 ± 389 mg/day for <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, 1091 ± 222 mg/day for <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>, and 1684 ± 181 or 1846 ± 152 mg/day for <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> (only subgroup data were available). Paracetamol was allowed in all trials as rescue medication, some other analgesics or drugs such as benzodiazepines, non‐steroidal anti‐inflammatory drugs, opioids or stable doses of selective serotonin reuptake inhibitors were permitted during the study phase in one trial (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>), and tramadol in another (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). The other three trials allowed none of these supplementary medications (<a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). </p> </section> <section id="CD007963-sec-0058"> <h5 class="title">Outcomes</h5> <p>Variables were evaluated after treatment for six weeks in <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>, 16 weeks in <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> and <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>, and 18 weeks in <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>. Withdrawals were recorded in detail. There were high percentages of dropouts, and common reasons for discontinuation included adverse effects, protocol violations and unsatisfactory responses to treatment. Most efficacy analyses were performed with an ITT analysis, which comprised all randomised participants regardless of completeness of treatment or follow‐up, based on the last observation carried forward (LOCF) principle. </p> <p>The outcome measures were similar among the four trials from the same series of studies. They all used a VAS for participants to report pain severity. For the three trials investigating painful diabetic neuropathy (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>) and the one trial of peripheral neuropathic pain (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>), the primary outcome was change in mean pain scores between baseline and each end of double‐blind treatment. The other trial compared the mean VAS score between groups during the last week of double‐blind treatment (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). Other efficacy variables used in the five trials included: participant's global assessment of therapeutic effect (GATE), Participant‐rated Global Impression of Change (PGIC), onset of therapeutic effect, rate of responders, pain relief, effect on evoked pain, durability of treatment effect, and sleep disturbances. Quality of life was assessed by SF‐36 and the Profile of Mood States (POMS) on up to five occasions, or Neuropathic Pain Symptom Inventory (NPSI) throughout the double‐blind phase. In addition, all included trials reported adverse effects during the treatment phase and clearly described serious adverse effects and adverse effects leading to discontinuation. </p> </section> </section> <section id="CD007963-sec-0059"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies on inspection of the full text (<a href="./references#CD007963-bbs2-0006" title="BesiE , BonifaceDR , CreggR , ZakrzewskaJM . Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). Journal of Headache and Pain2015;16:563. ">Besi 2015</a>; <a href="./references#CD007963-bbs2-0007" title="BeydounA , D'SouzaJ . Oxcarbazepine versus carbamazepine in patients with new onset trigeminal neuralgia result of double blind comparative trial [abstract no.P06.116]. Neurology2002;58 Suppl 3:A471. ">Beydoun 2002</a>; <a href="./references#CD007963-bbs2-0008" title="BeydounS , AlarcónF , MangatS , WanY . Long‐term safety and tolerability of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2007;115(4):284‐8. ">Beydoun 2007</a>; <a href="./references#CD007963-bbs2-0009" title="Brainer‐LimaP , NaylorF . Oxcarbazepine for cancer‐related neuropathic pain and opiate detoxification. 22nd Annual Meeting of the American Pain Society; 2003 March 20‐23; Chicago (IL). 2003. ">Brainer‐Lima 2003</a>; <a href="./references#CD007963-bbs2-0010" title="GongJJ . A randomised controlled trial of 3 drugs for the treatment of idiopathic trigeminal neuralgia [3种药物治疗原发性三叉神经痛的随机对照试验]. Journal of China Traditional Chinese Medicine Information2010;2(12):74. ">Gong 2010</a>; <a href="./references#CD007963-bbs2-0011" title="HuYJ . The comparative efficacy of oxcarbazepine and carbamazepine for trigeminal neuralgia [奥卡西平与卡马西平治疗三次神经痛的疗效对比]. Shandong Medical Journal2010;50(25):107. ">Hu 2010</a>; <a href="./references#CD007963-bbs2-0012" title="LiG , ZhaQ , ChenJZ , CaoQH , PengWJ . Clinical efficacy of oxcarbazepine for primary trigeminal neuralgia [奥卡西平治疗原发性三叉神经痛临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(3):167‐8. ">Li 2011</a>; <a href="./references#CD007963-bbs2-0013" title="LiebelJ . Results of a double‐blind trial comparing oxcarbazepine (OXC) vs carbamazepine (CBZ) in newly diagnosed, untreated patients with trigeminal neuralgia. Journal of the Neurological Sciences2001;187 Suppl 1:S5. ">Liebel 2001</a>; <a href="./references#CD007963-bbs2-0014" title="LindströmP . The analgesic effect of carbamazepine in trigeminal neuralgia. Pain1987;28 Suppl 4:S85. ">Lindström 1987</a>; <a href="./references#CD007963-bbs2-0015" title="Symptom‐based treatment for neuropathic pain in spinal cord injured patients, randomized clinical trial, 2014. clinicaltrials.gov/ct2/show/study/NCT02180880?term=oxcarbazepine&amp;rank=34 (accessed 2 October 2015). MinK , OhY , LeeSH , RyuJS . Symptom‐based treatment of neuropathic pain in spinal cord‐injured patients: a randomized crossover clinical trial. American Journal of Physical Medicine &amp; Rehabilitation2016;95(5):330‐8. ">Min 2016</a>; <a href="./references#CD007963-bbs2-0016" title="RémillardG . Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia1994;35 Suppl 3:S28‐9. ">Rémillard 1994</a>; <a href="./references#CD007963-bbs2-0017" title="Venancio‐RamirezL , Hernández‐SantosJR , Tenopala‐VillegasS , Torres‐HuertaJC , Rivera‐LeónG , Canseco‐AguilarC . Comparison of oxcarbazepine and gabapentin at standard dose in treatment of pain for postherpetic neuropathy. Revista Mexicana de Anestesiologia2004;27(3):129‐33. ">Venancio‐Ramirez 2004</a>; <a href="./references#CD007963-bbs2-0018" title="ZhouJF . A clinical research on the pharmacological treatment of trigeminal neuralgia [药物治疗三叉神经痛的临床研究]. Medical Information Operations Sciences Fascicule2010;1:89. ">Zhou 2010</a>). Reasons for exclusion were: trials only reported the results in abstract form but they did not refer to any useable data of the prespecified outcome measures of our protocol; we contacted the sponsor company but they could not find the full text or any useful data (<a href="./references#CD007963-bbs2-0007" title="BeydounA , D'SouzaJ . Oxcarbazepine versus carbamazepine in patients with new onset trigeminal neuralgia result of double blind comparative trial [abstract no.P06.116]. Neurology2002;58 Suppl 3:A471. ">Beydoun 2002</a>; <a href="./references#CD007963-bbs2-0009" title="Brainer‐LimaP , NaylorF . Oxcarbazepine for cancer‐related neuropathic pain and opiate detoxification. 22nd Annual Meeting of the American Pain Society; 2003 March 20‐23; Chicago (IL). 2003. ">Brainer‐Lima 2003</a>; <a href="./references#CD007963-bbs2-0013" title="LiebelJ . Results of a double‐blind trial comparing oxcarbazepine (OXC) vs carbamazepine (CBZ) in newly diagnosed, untreated patients with trigeminal neuralgia. Journal of the Neurological Sciences2001;187 Suppl 1:S5. ">Liebel 2001</a>); open‐label studies evaluating the changes between the pre‐ and post‐treatment conditions, without control groups (<a href="./references#CD007963-bbs2-0008" title="BeydounS , AlarcónF , MangatS , WanY . Long‐term safety and tolerability of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2007;115(4):284‐8. ">Beydoun 2007</a>; <a href="./references#CD007963-bbs2-0016" title="RémillardG . Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia1994;35 Suppl 3:S28‐9. ">Rémillard 1994</a>); not blinded or of an adequately randomised design (<a href="./references#CD007963-bbs2-0006" title="BesiE , BonifaceDR , CreggR , ZakrzewskaJM . Comparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP). Journal of Headache and Pain2015;16:563. ">Besi 2015</a>; <a href="./references#CD007963-bbs2-0010" title="GongJJ . A randomised controlled trial of 3 drugs for the treatment of idiopathic trigeminal neuralgia [3种药物治疗原发性三叉神经痛的随机对照试验]. Journal of China Traditional Chinese Medicine Information2010;2(12):74. ">Gong 2010</a>; <a href="./references#CD007963-bbs2-0011" title="HuYJ . The comparative efficacy of oxcarbazepine and carbamazepine for trigeminal neuralgia [奥卡西平与卡马西平治疗三次神经痛的疗效对比]. Shandong Medical Journal2010;50(25):107. ">Hu 2010</a>; <a href="./references#CD007963-bbs2-0012" title="LiG , ZhaQ , ChenJZ , CaoQH , PengWJ . Clinical efficacy of oxcarbazepine for primary trigeminal neuralgia [奥卡西平治疗原发性三叉神经痛临床观察]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine2011;21(3):167‐8. ">Li 2011</a>; <a href="./references#CD007963-bbs2-0018" title="ZhouJF . A clinical research on the pharmacological treatment of trigeminal neuralgia [药物治疗三叉神经痛的临床研究]. Medical Information Operations Sciences Fascicule2010;1:89. ">Zhou 2010</a>); or short follow‐up duration, less than the minimum we specified in our protocol (<a href="./references#CD007963-bbs2-0014" title="LindströmP . The analgesic effect of carbamazepine in trigeminal neuralgia. Pain1987;28 Suppl 4:S85. ">Lindström 1987</a>; <a href="./references#CD007963-bbs2-0015" title="Symptom‐based treatment for neuropathic pain in spinal cord injured patients, randomized clinical trial, 2014. clinicaltrials.gov/ct2/show/study/NCT02180880?term=oxcarbazepine&amp;rank=34 (accessed 2 October 2015). MinK , OhY , LeeSH , RyuJS . Symptom‐based treatment of neuropathic pain in spinal cord‐injured patients: a randomized crossover clinical trial. American Journal of Physical Medicine &amp; Rehabilitation2016;95(5):330‐8. ">Min 2016</a>; <a href="./references#CD007963-bbs2-0017" title="Venancio‐RamirezL , Hernández‐SantosJR , Tenopala‐VillegasS , Torres‐HuertaJC , Rivera‐LeónG , Canseco‐AguilarC . Comparison of oxcarbazepine and gabapentin at standard dose in treatment of pain for postherpetic neuropathy. Revista Mexicana de Anestesiologia2004;27(3):129‐33. ">Venancio‐Ramirez 2004</a>). See <a href="./references#CD007963-sec-0125" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD007963-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>The five included trials all had a moderately large sample of participants and standardised protocols. All included studies were multicentre, placebo‐controlled, double‐blind trials. </p> <section id="CD007963-sec-0061"> <h4 class="title">Allocation</h4> <p>Based on the published methods, we considered allocation sequence generation and concealment to be well performed to minimise bias in four trials (<a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). For the only trial involving participants with radiculopathy, we were unable to obtain detailed information about the methods of allocation (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>) (<a href="./references#CD007963-sec-0124" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD007963-sec-0062"> <h4 class="title">Blinding</h4> <p>In the double‐blind phase of the four trials of similar design, matched placebos were used and administered in the same way with the same initiated doses and increments (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). The participants and personnel involved in the study performance and assessment were likely to have been blinded. In <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>, participants were asked to guess which treatment they had received after each treatment period, and the correct guess rate was very high (67/83 after the first treatment period and 70/83 after the second treatment period). This might be the result of many participants experiencing adverse effects with oxcarbazepine, which could lead to unblinding. We agree with the trial authors' evaluation that the influence could go in both directions; some participants might think the treatment was ineffective because of the obvious adverse effects, while others might overrate the effect knowing they were on active treatment. It is difficult to evaluate the extent of possible bias in each direction (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). Such a risk of bias may also apply to the other four included studies, but no relevant data were reported, so we considered these trials at unclear risk of performance bias for blinding of participants (<a href="./references#CD007963-sec-0124" title="">Characteristics of included studies</a> table). </p> </section> <section id="CD007963-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>All five trials clearly reported withdrawals after randomisation. The main reasons for discontinuation, in both the oxcarbazepine and placebo groups, included adverse effects, lack of efficacy and protocol violations, but the numbers of participants with incomplete outcome data and the reasons for withdrawal were imbalanced across groups (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). To deal with missing outcome data, the trial authors performed ITT analyses using the LOCF approach, whereby all withdrawn participants had the mean weekly VAS score from their last week of treatment carried forward for assessment. However, participants might have withdrawn before they found any obvious effect, so imputing outcomes in this way for missing participants (especially for early withdrawals) could have led to an underestimation of the true intervention effect. </p> <p>There were no detailed descriptions of the results for completers and dropouts in the reports, so we could not conduct an ITT analysis by regarding participants with missing outcome data as failures with no response. Since the dropout rates were high or very high in all groups (19.1% to 56.3%), and they were significantly higher in the oxcarbazepine groups than the control groups (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>), a potential risk of bias against oxcarbazepine due to incomplete outcome data should be considered (<a href="./references#CD007963-bbs2-0044" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). This led us to downgrade the quality of the evidence. </p> </section> <section id="CD007963-sec-0064"> <h4 class="title">Selective reporting</h4> <p>All outcomes specified in the protocols were reported in the published reports, so the four studies published in full text were probably free from selective reporting bias (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). For the one trial that was only published in abstract form, all expected outcomes in the protocol were reported online (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). To avoid publication bias, we included the unpublished data from this trial. </p> </section> <section id="CD007963-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other potential source of bias.</p> <section id="CD007963-sec-0066"> <h5 class="title">Overall risk of bias</h5> <p>We rated all five trials as at a high overall risk of bias mainly because of a large and imbalanced proportion of missing outcome data across groups, especially those due to adverse effects of the interventions (<a href="#CD007963-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD007963-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007963-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> </section> <section id="CD007963-sec-0067"> <h3 class="title" id="CD007963-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD007963-tbl-0001"><b>Summary of findings for the main comparison</b> Oxcarbazepine versus placebo for painful diabetic neuropathy</a> </p> <p>We planned to evaluate the effects of treatment after eight weeks, but we could not extract the relevant data because 1. in the cross‐over trial, oxcarbazepine or placebo was used for only six weeks in each treatment period (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>); 2. the other four included trials reported outcomes 16 weeks after starting the treatment; and 3. the rates of change in the measured outcomes per week were not constant (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). Therefore, we extracted and analysed data measured at the end of the follow‐up period in each study, and subgrouped outcomes according to different follow‐up durations where possible. We analysed the effects of four daily doses (600 mg, 1200 mg, 1800 mg and 2400 mg) of oral oxcarbazepine versus placebo for painful diabetic neuropathy; neuropathic pain due to radiculopathy; or due to polyneuropathy, peripheral nerve injury or postherpetic neuralgia. There were no eligible trials of oxcarbazepine at other doses, other administration routes, compared to any other intervention or for other types of neuropathic pain. </p> <p>Four included trials measured pain severity on a 100‐unit VAS, where 'no pain' was at the left end and 'worst pain imaginable' at the right end (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). The other trial used an 11‐point NRS to rate participants' pain intensity, with 0 being 'no pain' and 10 'worst possible pain' (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). Authors did not always report the proportion of participants whose pain scores were reduced by at least 50% or at least 30% from the baseline, which were the primary and first secondary outcome measures in our review. One of the primary efficacy variables in the trial was the mean change in pain score from baseline to the end of double‐blind treatment, but there was extensive variability in the results. Since different types of neuropathy have different mechanisms and characteristics that could affect treatment efficacy, we presented results for each condition separately where possible, with a separate heading for neuropathic pain of mixed aetiologies because the results for each different condition were not available from <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>. </p> <section id="CD007963-sec-0068"> <h4 class="title">Oxcarbazepine versus placebo for painful diabetic neuropathy</h4> <p>Three trials investigated the effects of oxcarbazepine in painful diabetic neuropathy (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). </p> <section id="CD007963-sec-0069"> <h5 class="title">Primary outcome</h5> <section id="CD007963-sec-0070"> <h6 class="title">Reduction in participant‐reported pain scores by at least 50% from the baseline</h6> <p><a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a> showed that the proportion of participants experiencing at least 50% pain relief was 24/69 (34.8%) in the oxcarbazepine 1800 mg/day group (34.8%) versus 14/77 (18.2%) in the placebo group (RR 1.91, 95% CI 1.08 to 3.39; P = 0.03; n = 146; <a href="./references#CD007963-fig-0007" title="">Analysis 1.1</a>; <a href="#CD007963-fig-0003">Figure 3</a>). The NNTB was 6 (95% CI 3 to 41). </p> <div class="figure" id="CD007963-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.1 Reduction in participant‐reported pain scores by at least 50% from the baseline." data-id="CD007963-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.1 Reduction in participant‐reported pain scores by at least 50% from the baseline. </p> </div> </div> </div> <p>There were no data from <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> or <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a> for this outcome, so we were unable to resolve the discrepancies between the included trials. The included trial had significantly higher withdrawal rates from the oxcarbazepine group than the control group, so pooled results may also be at risk of bias from incomplete outcome data. </p> <p>We assessed the quality of the evidence as very low (imprecision, publication bias, inconsistency and study limitations were all present to a serious degree) (<a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD007963-sec-0071"> <h5 class="title">Secondary outcomes</h5> <section id="CD007963-sec-0072"> <h6 class="title">Reduction in participant‐reported pain scores by at least 30% from the baseline</h6> <p><a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a> provided data for comparisons between baseline and the 16th treatment week. A higher percentage of participants in the oxcarbazepine group experienced at least 30% pain relief compared with placebo (31/69 (44.9%) participants with oxcarbazepine versus 22/77 (28.6%) with placebo; RR 1.57, 95% CI 1.01 to 2.44; P = 0.04; n = 146; <a href="./references#CD007963-fig-0008" title="">Analysis 1.2</a>). The NNTB was 6 (95% CI 3 to 114). </p> <p><a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> and <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a> did not provide data for reduction in participant‐reported pain scores by at least 30% from the baseline. </p> <p>We assessed the quality of this evidence as very low (imprecision, publication bias, inconsistency and study limitations were all present to a serious degree) (<a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD007963-sec-0073"> <h6 class="title">Participants' global impression of their change in pain</h6> <p>Two studies reported data for participants' global impression of their change in pain (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>); the other study reported only that there was no significant difference (<a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). </p> <p>The two studies providing data used GATE to assess participants' global impression of change in neuropathic pain, applying a 7‐point Likert scale with scores ranging from ‐3 (very much improved) to 3 (very much deteriorated). We compared the proportion of participants in the oxcarbazepine and placebo groups who reported all degrees of improvement (‐3 to ‐1 points for GATE) and who were 'much' or 'very much' improved (‐3 to ‐2 points for GATE) after 16 weeks of treatment. The meta‐analysis was at potential risk of bias from imbalanced incomplete outcome data and inconsistent placebo responses (<a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, more participants who received oxcarbazepine felt globally improved compared with participants who received placebo (50/60 (72.5%) with participants versus 31/77 (40.3%) with placebo; RR 1.80, 95% CI 1.32 to 2.45; P = 0.0002; n = 146). </p> <p>Pooling relevant data from <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> and <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, pain was 'much' or 'very much' improved in 150/327 (45.9%) participants receiving oxcarbazepine versus 50/166 (30.1%) participants receiving placebo (RR 1.46, 95% CI 1.13 to 1.88; P = 0.004; n = 493; <a href="./references#CD007963-fig-0009" title="">Analysis 1.3</a>; <a href="#CD007963-fig-0004">Figure 4</a>). The corresponding NNTB score change across all dosages of oxcarbazepine was 6 (95% CI 4 to 14). However, there was a high degree of heterogeneity between the two included studies (I² = 74%, Chi² = 3.84, degrees of freedom (df) = 1, P = 0.05). </p> <div class="figure" id="CD007963-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.3 Participant' global impression of their change in pain." data-id="CD007963-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.3 Participant' global impression of their change in pain. </p> </div> </div> </div> <p>Overall, we judged these data at very low quality because of serious study limitations (attrition bias), inconsistency and a serious risk of publication bias. </p> </section> <section id="CD007963-sec-0074"> <h6 class="title">Overall quality of life measures</h6> <p>All studies performed the SF‐36 Health Survey on different occasions during the double‐blind phase including at the eighth week, which was when we specified to measure this outcome in our protocol (<a href="./references#CD007963-bbs2-0069" title="ZhouM , HeL , YangM , ChenN , GuoJ , LiQ , YangX , YangJ , ZhuC . Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD007963] ">Zhou 2009</a>). However, the scores were not recorded for each follow‐up period and some information could only be obtained at week 16 or at the final visit. In <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, the aggregate mental health score was significantly different between oxcarbazepine‐treated and placebo‐treated participants (in favour of oxcarbazepine, P = 0.03). In <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> and <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>, the trial authors stated only that there were no significant differences between the oxcarbazepine groups and placebo groups for the quality of life questionnaire. </p> </section> <section id="CD007963-sec-0075"> <h6 class="title">Adverse effects</h6> <p>Adverse effects often started during the titration period and resolved before studies finished. Frequently reported adverse effects included dizziness, headache, nausea, somnolence, fatigue, vomiting, back pain, diarrhoea, tremor, skin rash and blurred vision. Most adverse effects were mild to moderate in intensity and resulted in dosage adjustment. </p> <section id="CD007963-sec-0076"> <p><b>Adverse effects leading to withdrawal</b></p> <p>Pooled data from three studies showed that more participants receiving oxcarbazepine experienced adverse effects leading to withdrawal than participants receiving placebo (102/398 (25.6%) with oxcarbazepine group versus 16/236 (6.8%) with placebo group discontinued treatment prematurely owing to adverse effects (RR 3.83, 95% CI 2.29 to 6.40; P &lt; 0.00001; n = 634; <a href="./references#CD007963-fig-0010" title="">Analysis 1.4</a>) (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). </p> </section> <section id="CD007963-sec-0077"> <p><b>Serious adverse effects</b></p> <p>Serious adverse effects occurred in a small number of participants; some effects were considered related to treatment, such as erythema multiforme, Steven Johnson syndrome, severe fatigue, weakness, light‐headedness and headache leading to hospitalisations. Although the trials each reported no significant difference between oxcarbazepine and placebo for serious adverse events, our meta‐analysis of the results showed a higher frequency of serious adverse events in the oxcarbazepine group (RR 3.65, 95% CI 1.45 to 9.20; P = 0.006; n = 634; <a href="./references#CD007963-fig-0010" title="">Analysis 1.4</a>; <a href="#CD007963-fig-0005">Figure 5</a>; <a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>). The NNTH, defined as number with a serious adverse drug reaction was 17 (95% CI 11 to 42). The I² statistic was 0% for both of the above two pooled results, indicating no important heterogeneity across included trials. </p> <div class="figure" id="CD007963-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.4 Adverse effects." data-id="CD007963-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.4 Adverse effects. </p> </div> </div> </div> <p>We judged this evidence as moderate quality. The low event rate reduced the precision of the effect estimate. </p> </section> </section> </section> <section id="CD007963-sec-0078"> <h5 class="title">Post‐hoc subgroup analysis</h5> <section id="CD007963-sec-0079"> <h6 class="title">Different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy (600 mg/day, 1200 mg/day, 1800 mg/day) </h6> <section id="CD007963-sec-0080"> <p><b>Participants' global impression of their change in pain</b></p> <p>We performed a subgroup analysis with participants with painful diabetic neuropathy receiving different doses of oxcarbazepine (600 mg/day, 1200 mg/day or 1800 mg/day). There was suggestion of a dose‐effect relationship in one dose‐ranging study (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>). Although <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> used a higher daily dose (up to oxcarbazepine 1800 mg/day to 2400 mg/day), we did not extract data from this trial for dose‐effect analysis because of the many differences in pain aetiology, study design and treatment duration. </p> <p>Pooled data from two studies showed that the percentage of participants who improved 'much' or 'very much' in pain (‐3 to ‐2 points for GATE) was greater in the 1800 mg/day oxcarbazepine group (76/157 (48.4%) with oxcarbazepine 1800 mg/day versus 50/166 (30.1%) with placebo; RR 1.64, 95% CI 1.01 to 2.67; P = 0.05; n = 323) (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>). In <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>, the results showed no difference between oxcarbazepine 600 mg/day or 1200 mg/day and placebo (600 mg/day: 30/83 (36.1%) with oxcarbazepine 600 mg/day versus 33/89 (37.1%) with placebo; RR 0.97, 95% CI 0.66 to 1.45; P = 0.90; n = 176; 1200 mg/day: 44/87 (50.6%) with oxcarbazepine 1200 mg/day versus 33/89 (37.1%) with placebo; RR 1.36, 95% CI 0.97 to 1.92; P = 0.07; n = 176; <a href="./references#CD007963-fig-0011" title="">Analysis 2.1</a>; <a href="#CD007963-fig-0006">Figure 6</a>). NNTB score change could not be calculated for the oxcarbazepine 600 mg/day group because the event rate was lower than that of the placebo group. The NNTB score change was 7 (95% CI 4 to 97) in the oxcarbazepine 1200 mg/day group and 6 (95% CI 4 to 13) in the oxcarbazepine 1800 mg/day group. </p> <div class="figure" id="CD007963-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 4.1 Participants who improved much or very much after 16‐week treatment." data-id="CD007963-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 4.1 Participants who improved much or very much after 16‐week treatment. </p> </div> </div> </div> </section> <section id="CD007963-sec-0081"> <p><b>Adverse effects leading to withdrawal from treatment</b></p> <p>Adverse effects leading to discontinuation occurred more frequently with the higher daily doses of oxcarbazepine (1200 mg/day: 38/158 with oxcarbazepine 1200 mg/day versus 10/159 with placebo; RR 3.83, 95% CI 1.97 to 7.41; P &lt; 0.0001; n = 317; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; 1800 mg/day: 55/157 with oxcarbazepine 1800 mg/day versus 12/166 with placebo; RR 4.83, 95% CI 2.68 to 8.70; P &lt; 0.00001; n = 323; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>). In <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>, the result for adverse effects leading to withdrawal between oxcarbazepine 600 mg/day and placebo was imprecise and did not rule out equivalence (RR 1.61, 95% CI 0.60 to 4.32; P = 0.35; n = 172) (<a href="./references#CD007963-fig-0012" title="">Analysis 2.2</a>). Although the rates of adverse effects increased with dose, the CIs were wide and overlapping. </p> </section> <section id="CD007963-sec-0082"> <p><b>Serious adverse effects</b></p> <p>Comparisons of serious adverse effects in the oxcarbazepine and placebo groups showed a similar trend towards a dose‐dependent relationship with oxcarbazepine 1800 mg/day having the highest percentage of serious adverse effects (oxcarbazepine 1800 mg/day: 17/157 (10.8%); n = 323; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; oxcarbazepine 1200 mg/day: 14/158 (8.9%); n = 317; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; oxcarbazepine 600 mg/day: 2/83 (2.4%); n = 172; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>). Compared to the placebo group, more people receiving the two higher doses of oxcarbazepine had adverse effects (<a href="./references#CD007963-fig-0013" title="">Analysis 2.3</a>). The NNTH score was 78 (95% CI 19 to ∞) for oxcarbazepine 600 mg/day, 14 (95% CI 8 to 49) for oxcarbazepine 1200 mg/day and 12 (95% CI 7 to 33) for oxcarbazepine 1800 mg/day. </p> </section> </section> </section> </section> <section id="CD007963-sec-0083"> <h4 class="title">Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy</h4> <p>We found one trial including 145 participants with radiculopathy comparing oxcarbazepine versus placebo (<a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). </p> <section id="CD007963-sec-0084"> <h5 class="title">Primary outcome</h5> <section id="CD007963-sec-0085"> <h6 class="title">Reduction in participant‐reported pain scores by at least 50% from the baseline</h6> <p>Seven of 70 (10.0%) participants receiving oxcarbazepine had at least 50% pain relief versus 14/74 (18.9%) participants receiving placebo (RR 0.53, 95% CI 0.23 to 1.23; P = 0.14; n = 144; <a href="./references#CD007963-fig-0014" title="">Analysis 3.1</a>). </p> <p>Low event rates and the small size of the study made these results very imprecise. The trial was at high risk of attrition bias. </p> </section> </section> <section id="CD007963-sec-0086"> <h5 class="title">Secondary outcomes</h5> <section id="CD007963-sec-0087"> <h6 class="title">Reduction in participant‐reported pain scores by at least 30% from the baseline</h6> <p>The trial did not report reduction in participant‐reported pain scores by at least 30% from the baseline. </p> </section> <section id="CD007963-sec-0088"> <h6 class="title">Participants' global impression of their change in pain</h6> <p>The number of participants improved (all degrees) was 35/71 (49.3%) in the oxcarbazepine group versus 27/74 (36.5%) in the placebo group (RR 1.35, 95% CI 0.92 to 1.98; P = 0.12; n = 145) and the number of participants who 'much' or 'very much' improved was 17/71 (23.9%) in the oxcarbazepine group versus 11/74 (14.9%) in the placebo group (RR 1.61, 95% CI 0.81 to 3.20; P = 0.17; n = 145; <a href="./references#CD007963-fig-0015" title="">Analysis 3.2</a>). </p> <p>These results were imprecise and, although they favoured oxcarbazepine, did not rule out a lack of effect. The trial was at high risk of attrition bias. </p> </section> <section id="CD007963-sec-0089"> <h6 class="title">Overall quality of life measures</h6> <p>The trial did not report overall quality of life measures.</p> </section> <section id="CD007963-sec-0090"> <h6 class="title">Adverse effects</h6> <section id="CD007963-sec-0091"> <p><b>Any adverse effect</b></p> <p>In <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>, the proportion of participants who experienced any type of adverse effect was 68/71 (95.8%) in the oxcarbazepine group and 58/74 (78.4%) in the placebo group, with therefore a slightly higher rate of adverse effects with oxcarbazepine (RR 1.22, 95% CI 1.07 to 1.39; P = 0.002; n = 145). </p> </section> <section id="CD007963-sec-0092"> <p><b>Adverse effects leading to withdrawal from treatment</b></p> <p>The proportion of participants who withdrew due to adverse effects was also higher in the oxcarbazepine group than in the placebo group (30/71 (42.3%) participants with oxcarbazepine versus 11/74 (14.9%) participants with placebo; RR 2.84, 95% CI 1.55 to 5.23; P = 0.0008; n = 145). </p> </section> <section id="CD007963-sec-0093"> <p><b>Serious adverse effects</b></p> <p>There were six serious adverse effects (8.5%) in the oxcarbazepine group and two serious adverse effects (2.7%), including one death, in the control group (RR 3.13, 95% CI 0.65 to 14.98; P = 0.15; n = 145) (<a href="./references#CD007963-fig-0016" title="">Analysis 3.3</a>). The size of the trial and the low event rate made this result very imprecise. The trial was at high risk of attrition bias. </p> </section> </section> </section> </section> <section id="CD007963-sec-0094"> <h4 class="title">Oxcarbazepine versus placebo for neuropathic pain of various origins</h4> <p>We found one trial comparing oxcarbazepine versus placebo for neuropathic pain of various origins. <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> was a cross‐over study of 83 participants with peripheral neuropathic pain due to polyneuropathy, surgical or traumatic nerve injury, or postherpetic neuralgia. We attempted to contact the authors to obtain separate data for each treated condition but without success. Therefore, we presented combined results of participants with different types of neuropathic pain. </p> <p>The investigators performed "repeated‐measurements analysis of variance (ANOVA) with treatment and phenotype‐treatment interaction as factors, baseline value as covariate, patient as random effect, and period as fixed effect for continuous outcomes". They used Fisher's exact test or McNemar's change test for dichotomous outcomes. </p> <section id="CD007963-sec-0095"> <h5 class="title">Primary outcome</h5> <section id="CD007963-sec-0096"> <h6 class="title">Reduction in participant‐reported pain scores by at least 50% from the baseline</h6> <p><a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> reported that 16/83 (19.3%) participants had a 50% or more reduction in total pain score on oxcarbazepine and 4/83 (4.8%) participants receiving placebo. The NNTB was 7 (95% CI 4 to 22). The trial was at high risk of attrition bias and unblinding. </p> </section> </section> <section id="CD007963-sec-0097"> <h5 class="title">Secondary outcome measures</h5> <section id="CD007963-sec-0098"> <h6 class="title">Reduction in participant‐reported pain scores by at least 30% from the baseline</h6> <p>The trial did not report reduction in participant‐reported pain scores by at least 30% from the baseline. </p> </section> <section id="CD007963-sec-0099"> <h6 class="title">Participants' global impression of their change in pain</h6> <p>In <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>, investigators used PGIC to record participants' global impression of change, applying a 7‐point scale but scoring in the opposite direction to GATE (3 meant much improved, while ‐3 meant much worse). The trial authors reported no statistically significant difference between oxcarbazepine and placebo based on PGIC (score difference 0.23, P = 0.277). We could not obtain any relevant data from the trial for meta‐analysis. </p> </section> <section id="CD007963-sec-0100"> <h6 class="title">Overall quality of life measures</h6> <p><a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> reported that health‐related quality of life was unaltered by oxcarbazepine, but details were not available. </p> </section> <section id="CD007963-sec-0101"> <h6 class="title">Adverse effects</h6> <p>Among the mixed group of 83 participants in this trial, the trialists reported that adverse effects were the reason for all premature trial withdrawals (13/96 (13.5%) with oxcarbazepine versus 1/85 (1.2%) with placebo) (RR 11.51, 95% CI 1.54 to 86.15). They also found that most participants experienced adverse effects during oxcarbazepine treatment (frequency 94%, 95% CI 89% to 99%), but any adverse effect or at least one adverse effect was experienced by 36% of participants during placebo treatment (95% CI 26% to 47%). The trial authors listed several most frequently occurring adverse effects, and most were mild. No details were available to compare serious adverse effects between treatment and placebo groups (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). The trial was at high risk of attrition bias and unblinding. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007963-sec-0102" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007963-sec-0102">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007963-sec-0140">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007963-sec-0102"></div> <section id="CD007963-sec-0103"> <h3 class="title" id="CD007963-sec-0103">Summary of main results</h3> <p>We included five RCTs, involving 862 participants; all of which compared oral oxcarbazepine with placebo for the treatment of neuropathic pain. Three trials investigated people with painful diabetic neuropathy, one involved participants with neuropathic pain due to radiculopathy and one studied neuropathic pain of mixed aetiologies. Four trials had similar designs, methods, treatment and follow‐up periods, which allowed for the pooling of some, but not all, relevant efficacy and safety data (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>; <a href="./references#CD007963-bbs2-0005" title="Multicenter, double‐blind, randomized, placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to radiculopathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=429&amp;productid=330 (accessed 2 October 2015). HardenRN , UrniaszKL , HopwoodM , WanY . Efficacy and safety of oxcarbazepine in patients with neuropathic pain due to radiculopathy: a double‐blind, randomized, placebo‐controlled study. Neurology2005;64 Suppl 1:A120‐1. ">Novartis 2004</a>). The results indicated a possible slight effect for oxcarbazepine in relieving painful DPN (measured as at least 50% and at least 30% pain relief from baseline on a VAS) but this evidence was of very low quality. Oxcarbazepine also increased numbers of people 'much' or 'very much' improved according to the participant's global impression of change, but with high heterogeneity (<a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the quality of the evidence for each outcome measure to very low according to GRADE considerations, because of the small number of included studies and participants, inconsistency among studies, imprecision, attribution bias and because we strongly suspected publication bias (<a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>). As a result, we are uncertain whether oral oxcarbazepine is effective for the treatment of painful diabetic neuropathy. </p> <p>Results from the subgroup analyses of different daily doses in DPN suggested a trend towards a dose‐effect relationship for global impression of improvement in pain and adverse effects. The highest daily dose of oxcarbazepine (1800 mg/day) had the greatest effect on pain relief but also led to the most adverse effects, especially serious ones. </p> <p>In people with neuropathic pain of mixed aetiologies (polyneuropathy, surgical or traumatic nerve injury, or postherpetic neuralgia), oxcarbazepine also increased the number of people with at least 50% pain relief from baseline compared to placebo. For participants with radiculopathy, data from one trial showed that oxcarbazepine neither relieved pain nor improved participants' global impression of change compared to placebo. However, for each condition, data were available from only a single trial with a small sample size, which also led the quality of evidence to be low.  </p> <p>The benefits of oxcarbazepine were seen in two studies that used a higher dose (1800 mg/day to 2400 mg/day) of oxcarbazepine (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>). The other two studies included diabetic neuropathy trials found no significant differences between each dose of oxcarbazepine and placebo (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>), although there was a statistical trend favouring the two higher doses (1200 mg/day and 1800 mg/day) (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>). Neither of these studies were included a in meta‐analysis, which is thus heavily biased towards the reports that found benefit from oxcarbazepine. The investigators themselves put forward a number of factors to explain the differences in outcome among the trials. Besides the higher dose that was used in <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, its lower placebo response might at least partially contribute to the statistically significant findings. In the placebo group of <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, the mean change of VAS scores from the baseline to treatment end was ‐14.7 units, and about 22% of participants experienced an obvious or significant improvement; the corresponding values were ‐19.1 units and 37.3% for <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> and ‐22.0 units for <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a> (percentage of improved participants was not reported). This phenomenon can be partly explained by the substantial variation in placebo effect among people with painful diabetic neuropathy (<a href="./references#CD007963-bbs2-0022" title="BackonjaM , GlanzmanRL . Gabapentin dosing for neuropathic pain: evidence from randomized placebo‐controlled clinical trials. Clinical Therapeutics2003;25(1):81‐104. ">Backonja 2003</a>; <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0037" title="EisenbergE , RiverY , ShifrinA , KrivoyN . Antiepileptic drugs in the treatment of neuropathic pain. Drugs2007;67(9):1265‐89. ">Eisenberg 2007</a>). Furthermore, the effect of withdrawals due to adverse effects should also be considered. In <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>, 6/77 (7.8%) participants withdrew from the placebo group because of adverse effects, compared to 19/69 (27.5%) participants who withdrew from the oxcarbazepine 1800 mg/day group. The percentage of withdrawals was lower in <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>, at 13/96 (13.5%), even with a higher daily dose of up to 1800 mg/day to 2400 mg/day. Withdrawals were comparable in the placebo group of <a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a> (6/89 (6.7%) participants) but withdrawals in the oxcarbazepine 1800 mg group were much higher (36/88 (40.9%) participants). Although analyses were based on ITT populations, the impact of different withdrawal rates on the treatment‐effect estimation cannot be overlooked for reasons mentioned in the <a href="#CD007963-sec-0060">Risk of bias in included studies</a> section. </p> <p>Most adverse effects related to the study drugs were reported as mild to moderate in severity; however, the proportions of both any effects and of effects leading to withdrawal were higher in the oxcarbazepine group than the placebo group. The frequency of such adverse effects appeared to be dose related, based on our analyses. </p> </section> <section id="CD007963-sec-0104"> <h3 class="title" id="CD007963-sec-0104">Overall completeness and applicability of evidence</h3> <p>The RCTs in the present review included participants with common causes of neuropathic pain, including painful diabetic neuropathy, radiculopathy and peripheral neuropathic pain due to mixed aetiologies (polyneuropathy, peripheral nerve injury and postherpetic neuralgia). Relevant data for any outcome measure were only available from at most three trials, and we found no trials in people with other causes of neuropathic pain. The included trials all compared oral oxcarbazepine with placebo for the treatment of neuropathic pain. Although sharing a similar design, the included trials reported some outcomes in different ways; this prevented pooling of data from the three diabetic neuropathy trials (<a href="./references#CD007963-bbs2-0001" title="Multicenter, double‐blind, randomized placebo‐control, parallel group study to evaluate the safety and efficacy of three doses of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). BeydounA , ShaibaniA , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: results of a dose‐ranging study. Acta Neurologica Scandinavica2006;113(6):395‐404. [PUBMED: 16674606] BeydounA , WanY , HopwoodM , LiebelJ . Results of a randomized, placebo‐controlled trial suggest oxcarbazepine has a therapeutic effect in the treatment of painful diabetic neuropathy. European Journal of Neurology2004;11 Suppl 2:101. ">Beydoun 2006</a>; <a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>; <a href="./references#CD007963-bbs2-0004" title="Multicenter, double‐blind, randomized, placebo‐control, parallel study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2003. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). GrosskopfJ , MazzolaJ , WanY , HopwoodM . A randomized, placebo‐controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurologica Scandinavica2006;114(3):177‐80. [PUBMED: 16911345] RiviereM‐E , WanY , HopwoodM , LiebelJ . Oxcarbazepine in the treatment of painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:101. ">Grosskopf 2006</a>). In fact, their results (such as reduction in pain intensity) were inconsistent. For some outcome measures, we could only obtain data from the single trial in which results favoured oxcarbazepine (<a href="./references#CD007963-bbs2-0003" title="Multicenter, double‐blind, randomized placebo‐control, parallel‐group study to evaluate the safety and efficacy of oxcarbazepine in patients with neuropathic pain due to diabetic neuropathy, 2005. www.novctrd.com/CtrdWeb/product.nov?diseaseid=141&amp;productid=330 (accessed 2 October 2015). DograS , BeydounS , HopwoodM , MazzolaJ , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. Journal of Pain2004;5(3 Suppl 1):S6. DograS , BeydounS , MazzolaJ , HopwoodM , WanY . Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Pain2005;9(5):543‐54. [PUBMED: 16139183] DograS , BeydounS , MazzolaJ , HopwoodM , WanY , LiebelJ . Oxcarbazepine provides pain relief in patients with painful diabetic neuropathy: a randomized, placebo‐controlled study. European Journal of Neurology2004;11 Suppl 2:92. ">Dogra 2005</a>). The two trials that reported no benefit did not provide data for the primary outcome or for some secondary outcomes (e.g. participant‐reported pain reduction scores of at least 30% from the baseline; all degrees of improvement in participants' global impression of their change in pain) when assessing the effects of oxcarbazepine in people with diabetic neuropathy. </p> <p>Most of our results came from one or two trials. We found no results of some trials published only as abstracts. For example, we were unable to obtain data from studies assessing the effectiveness of oxcarbazepine in participants with trigeminal neuralgia, since they were only published in abstract form or in reviews (<a href="./references#CD007963-bbs2-0023" title="BeydounA , SchmidtD , SouzaJ . Oxcarbazepine versus carbamazepine in trigeminal neuralgia: a meta‐analysis of three double‐blind comparative trials. Neurology2002;58 Suppl 3:A131. ">Beydoun 2002a</a>; <a href="./references#CD007963-bbs2-0024" title="BeydounA , SchmidtD , D'SouzaJ , on behalf of the oxcarbazepine study group. Meta‐analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. 21st American Pain Society Annual Meeting; 2002 Mar 14‐17; Baltimore (MD). ">Beydoun 2002b</a>; <a href="./references#CD007963-bbs2-0029" title="CarrazanaE , MikoshibaI . Rationale and evidence for the use of oxcarbazepine in neuropathic pain. Journal of Pain and Symptom Management2003;25(5 Suppl):S31‐5. ">Carrazana 2003</a>; <a href="./references#CD007963-bbs2-0054" title="NasreddineW , BeydounA . Oxcarbazepine in neuropathic pain. Expert Opinion on Investigational Drugs2007;16(10):1615‐25. ">Nasreddine 2007</a>). It is strongly suspected that some publication bias may be present. Overall the results of the review should be applied with caution. </p> <p>It has been suggested that some human leukocyte antigen (HLA) alleles (e.g. HLA‐B*1502 and HLA‐A*3101) are associated with carbamazepine‐induced skin‐related adverse drug reactions that are sometimes serious and potentially life‐threatening in certain populations (<a href="./references#CD007963-bbs2-0046" title="IllingPT , VivianJP , PurcellAW , RossjohnJ , McCluskeyJ . Human leukocyte antigen‐associated drug hypersensitivity. Current Opinion in Immunology2013;25(1):81‐9. ">Illing 2013</a>). This potential association was not investigated in included trials in this review. The data available were insufficient to assess rare adverse effects. </p> <p>As specified in the newly included trial, pain phenotype based on putative mechanism of pain might also predict response to treatment. <a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a> compared the effect of oxcarbazepine in participants with and without the irritable nociceptor phenotype, as defined by hypersensitivity and preserved small nerve fibre function. The investigators found that oxcarbazepine was more efficacious for relief of peripheral neuropathic pain among participants with the irritable nociceptor phenotype (<a href="./references#CD007963-bbs2-0002" title="Oxcarbazepine for the treatment of chronic peripheral neuropathic pain (IMIOXC). https://clinicaltrials.gov/ct2/show/study/NCT01302275?term=NCT01302275&amp;rank=1 2014 (accessed 2 October 2015). DemantDT , LundK , VollertJ , MaierC , SegerdahlM , FinnerupNB , et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain2014;155(11):2263‐73. [PUBMED: 25139589] ">Demant 2014</a>). Therefore, the investigators hypothesised that the inconsistent results of studies investigating analgesic effects of anticonvulsants with sodium channel blocking effects in people with neuropathic pain might be partly attributable to such pain phenotypes. These phenotypes were not distinguished in the other trials included in the present review, so we could not perform further analyses to test the hypothesis. </p> </section> <section id="CD007963-sec-0105"> <h3 class="title" id="CD007963-sec-0105">Quality of the evidence</h3> <p>Although the placebo response in neuropathic pain can vary considerably among trials, and is difficult to regulate and control, RCTs still provide the most powerful evidence on which to base conclusions about the effect of treatment (<a href="http://www.gradeworkinggroup.org/index.htm" target="_blank">GRADE</a>). The five included trials were well designed and conducted in multiple centres. However, risks of bias remain, mainly from incompleteness of outcome data and possible unblinding of participants due to obvious adverse effects. Two trials of oxcarbazepine in DPN remain unpublished and this introduces a potential risk of publication bias, particularly as the trials that did not provide data reported little or no benefit from oxcarbazepine. The considerable inconsistencies in placebo responses and outcomes of participants' global impression in the diabetic neuropathy trials could undermine the reliability of the combined results. Serious imprecision also exists, because the sample size and event numbers were small and the CI included both little or no effect and substantial effects. Mean pain severity at randomisation also differed from trial to trial but was not analysed further in this review because of limited data availability. These differences might impact the results to some extent. For these reasons, we rated the evidence quality for our main outcome measures as very low according to GRADE criteria (<a href="./full#CD007963-tbl-0001">summary of findings Table for the main comparison</a>; <a href="http://www.gradeworkinggroup.org/index.htm" target="_blank">GRADE</a>). </p> </section> <section id="CD007963-sec-0106"> <h3 class="title" id="CD007963-sec-0106">Potential biases in the review process</h3> <p>To reduce the risk of attrition bias, we performed meta‐analyses on an ITT population using the LOCF approach; imputing outcomes for missing participants in this way could have led to an underestimation of the true effect. We could not obtain enough data to conduct an ITT analysis by regarding participants with missing outcome data as failures with no response. </p> <p>We have searched systematically, including published and unpublished studies, without language restrictions. However, all the included studies were published in English, and most results came from small studies, and we found no results of some trials published only as abstracts. Therefore, publication bias should still be possible. </p> </section> <section id="CD007963-sec-0107"> <h3 class="title" id="CD007963-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>The efficacy of oxcarbazepine has also been investigated for types of neuropathic pain other than those assessed in the present review, for example trigeminal neuralgia. Several RCTs have reported comparable effectiveness of oxcarbazepine and carbamazepine in relieving pain and improving quality of life in participants with trigeminal neuralgia (<a href="./references#CD007963-bbs2-0023" title="BeydounA , SchmidtD , SouzaJ . Oxcarbazepine versus carbamazepine in trigeminal neuralgia: a meta‐analysis of three double‐blind comparative trials. Neurology2002;58 Suppl 3:A131. ">Beydoun 2002a</a>; <a href="./references#CD007963-bbs2-0024" title="BeydounA , SchmidtD , D'SouzaJ , on behalf of the oxcarbazepine study group. Meta‐analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. 21st American Pain Society Annual Meeting; 2002 Mar 14‐17; Baltimore (MD). ">Beydoun 2002b</a>; <a href="./references#CD007963-bbs2-0029" title="CarrazanaE , MikoshibaI . Rationale and evidence for the use of oxcarbazepine in neuropathic pain. Journal of Pain and Symptom Management2003;25(5 Suppl):S31‐5. ">Carrazana 2003</a>; <a href="./references#CD007963-bbs2-0054" title="NasreddineW , BeydounA . Oxcarbazepine in neuropathic pain. Expert Opinion on Investigational Drugs2007;16(10):1615‐25. ">Nasreddine 2007</a>). These studies have only been published as a meta‐analysis in abstract form (<a href="./references#CD007963-bbs2-0023" title="BeydounA , SchmidtD , SouzaJ . Oxcarbazepine versus carbamazepine in trigeminal neuralgia: a meta‐analysis of three double‐blind comparative trials. Neurology2002;58 Suppl 3:A131. ">Beydoun 2002a</a>; <a href="./references#CD007963-bbs2-0024" title="BeydounA , SchmidtD , D'SouzaJ , on behalf of the oxcarbazepine study group. Meta‐analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. 21st American Pain Society Annual Meeting; 2002 Mar 14‐17; Baltimore (MD). ">Beydoun 2002b</a>) or in reviews (<a href="./references#CD007963-bbs2-0029" title="CarrazanaE , MikoshibaI . Rationale and evidence for the use of oxcarbazepine in neuropathic pain. Journal of Pain and Symptom Management2003;25(5 Suppl):S31‐5. ">Carrazana 2003</a>; <a href="./references#CD007963-bbs2-0054" title="NasreddineW , BeydounA . Oxcarbazepine in neuropathic pain. Expert Opinion on Investigational Drugs2007;16(10):1615‐25. ">Nasreddine 2007</a>), in which detailed descriptions and data were unavailable. Thus, they could not be included in the current review. One postherpetic neuralgia study showed a significant decrease in VAS score and improvements in participants' quality of life but had an open‐label design (<a href="./references#CD007963-bbs2-0031" title="CriscuoloS , AulettaC , LippiS , BrogiF , BrogiA . Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. Acta Neurologica Scandinavica2005;111(4):229‐32. ">Criscuolo 2005</a>). As a result, we cannot draw any conclusion about oxcarbazepine for the treatment of these types of neuropathic pain. </p> <p>In agreement with the conclusions of our systematic review, the latest European Federation of Neurological Societies (EFNS) guidelines do not recommend oxcarbazepine for people with diabetic neuropathic pain because of insufficient and conflicting evidence (<a href="./references#CD007963-bbs2-0020" title="AttalN , CruccuG , HaanpääM , HanssonP , JensenTS , NurmikkoT , et al. EFNS Task Force. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology2006;13(11):1153‐69. ">Attal 2006</a>; <a href="./references#CD007963-bbs2-0021" title="AttalN , CruccuG , BaronR , HaanpääM , HanssonP , JensenTS , et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision. European Journal of Neurology2010;17(9):1113‐e88. [DOI: 10.1111/j.1468‐1311.2010.02999.x] ">Attal 2010</a>). However, these guidelines recommend oxcarbazepine as one of the first‐line drugs for classical trigeminal neuralgia. In one retrospective study of a large cohort of participants, investigators concluded that the efficacy of oxcarbazepine was comparable to that of carbamazepine in treating trigeminal neuralgia, and that oxcarbazepine had a greater tolerability (<a href="./references#CD007963-bbs2-0035" title="DiStefanoG , LaCesaS , TruiniA , CruccuG . Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. Journal of Headache and Pain2014;15:34. ">Di Stefano 2014</a>). In the absence of eligible RCTs, we were unable to draw any conclusions in this review about the use of oxcarbazepine for this type of neuropathic pain. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007963-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007963-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007963-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.1 Reduction in participant‐reported pain scores by at least 50% from the baseline." data-id="CD007963-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.1 Reduction in participant‐reported pain scores by at least 50% from the baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.3 Participant' global impression of their change in pain." data-id="CD007963-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.3 Participant' global impression of their change in pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.4 Adverse effects." data-id="CD007963-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 1.4 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 4.1 Participants who improved much or very much after 16‐week treatment." data-id="CD007963-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, outcome: 4.1 Participants who improved much or very much after 16‐week treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 1 Reduction in participant‐reported pain scores by at least 50% from the baseline." data-id="CD007963-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 1 Reduction in participant‐reported pain scores by at least 50% from the baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 2 Reduction in participant‐reported pain scores by at least 30% from the baseline." data-id="CD007963-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 2 Reduction in participant‐reported pain scores by at least 30% from the baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 3 Participant' global impression of their change in pain." data-id="CD007963-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 3 Participant' global impression of their change in pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 4 Adverse effects." data-id="CD007963-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 4 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 1 Participants who improved much or very much after 16‐week treatment." data-id="CD007963-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 1 Participants who improved much or very much after 16‐week treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 2 Adverse effects leading to withdrawals." data-id="CD007963-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 2 Adverse effects leading to withdrawals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 3 Serious adverse effects." data-id="CD007963-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy, Outcome 3 Serious adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy, Outcome 1 Reduction in participant‐reported pain scores by at least 50% from baseline." data-id="CD007963-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy, Outcome 1 Reduction in participant‐reported pain scores by at least 50% from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy, Outcome 2 Participant' global impression of therapeutic effect." data-id="CD007963-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy, Outcome 2 Participant' global impression of therapeutic effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007963-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/urn:x-wiley:14651858:media:CD007963:CD007963-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_t/tCD007963-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy, Outcome 3 Adverse effects." data-id="CD007963-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy, Outcome 3 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/media/CDSR/CD007963/image_n/nCD007963-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007963-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oxcarbazepine versus placebo for painful diabetic neuropathy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with painful diabetic neuropathy<br/> <b>Settings:</b> hospitals and clinics<br/> <b>Intervention:</b> oxcarbazepine </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oxcarbazepine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in participant‐reported pain scores by at least 50% from the baseline</b> <br/> VAS<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> <br/> (197 to 617) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.91</b> <br/> (1.08 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB 6</b> (95% CI 3 to 41) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in participant‐reported pain scores by at least 30% from the baseline</b> <br/> VAS<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>449 per 1000</b> <br/> (289 to 698) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.57</b> <br/> (1.01 to 2.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB 6</b> (95% CI 3 to 114) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants' global impression of their change in pain</b> <br/> Participant's global assessment of therapeutic effect, 'much' or 'very much'<br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>301 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>439 per 1000</b> <br/> (340 to 566) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/> (1.13 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>493<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTB 6</b> (95% CI 4 to 14) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse effects</b> <br/> Follow‐up: mean 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>91 per 1000</b> <br/> (36 to 230) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.65</b> <br/> (1.45 to 9.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>634<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNTH 17</b> (95% CI 11 to 42) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval;<b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded three times: once for inconsistency with other studies not included in the meta‐analysis, once for serious imprecision (small sample size and wide CI) and once for serious study limitations (number of withdrawals not balanced across groups, especially withdrawals due to adverse effects, which led to a high risk of attrition bias. A high risk of publication bias was present.<br/> <sup>2</sup>Downgraded three times: once for serious study limitations (number of withdrawals not balanced across groups, especially withdrawals due to adverse effects, which led to a high risk of attrition bias), once for inconsistency (a high degree of unexplained heterogeneity between the two included RCTs) and once for publication bias.<br/> <sup>3</sup>Downgraded once for serious imprecision. Event rate was low. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/full#CD007963-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007963-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Reduction in participant‐reported pain scores by at least 50% from the baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 16 weeks after starting treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.08, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Reduction in participant‐reported pain scores by at least 30% from the baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 16 weeks after starting the treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.01, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant' global impression of their change in pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All improved participants after 16‐week treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.32, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants who improved much or very much after 16‐week treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.13, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Adverse effects leading to withdrawal from treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.83 [2.29, 6.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Serious adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [1.45, 9.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007963-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants who improved much or very much after 16‐week treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oxcarbazepine 600 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.66, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Oxcarbazepine 1200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.97, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Oxcarbazepine 1800 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.01, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects leading to withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oxcarbazepine 600 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.60, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oxcarbazepine 1200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.83 [1.97, 7.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Oxcarbazepine 1800 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.83 [2.68, 8.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serious adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oxcarbazepine 600 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.20, 23.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Oxcarbazepine 1200 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [1.38, 15.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Oxcarbazepine 1800 mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [1.55, 13.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: different daily doses of oxcarbazepine versus placebo for painful diabetic neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007963-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Reduction in participant‐reported pain scores by at least 50% from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.23, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participant' global impression of therapeutic effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 All improved participants after 16‐week treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.92, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants who improved much or very much after 16‐week treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.81, 3.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Any adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.07, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Adverse effects leading to withdrawal from treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [1.55, 5.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Serious adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.65, 14.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oxcarbazepine versus placebo for neuropathic pain due to radiculopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007963.pub3/references#CD007963-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007963.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007963-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007963-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007963-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="pl#CD007963-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD007963-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007963-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007963\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007963\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007963\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007963\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007963\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007963.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007963.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007963.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007963.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007963.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716155203"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007963.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716155207"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007963.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d98974ac0f409',t:'MTc0MDcxNjE1NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 